134 related articles for article (PubMed ID: 8983296)
1. Modulation of toxicity following external beam irradiation preceded by high-dose rate brachytherapy in inoperable oesophageal cancer.
Taal BG; Aleman BM; Koning CC; Boot H
Eur J Cancer; 1996 Sep; 32A(10):1815-8. PubMed ID: 8983296
[TBL] [Abstract][Full Text] [Related]
2. High dose rate brachytherapy before external beam irradiation in inoperable oesophageal cancer.
Taal BG; Aleman BM; Koning CC; Boot H
Br J Cancer; 1996 Nov; 74(9):1452-7. PubMed ID: 8912544
[TBL] [Abstract][Full Text] [Related]
3. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
4. Palliation of dysphagia in advanced, metastatic or recurrent carcinoma oesophagus with high dose rate intraluminal brachytherapy--an eastern Indian experience of 35 cases.
Ghosh S; Sau S; Mitra S; Manna A; Ghosh K
J Indian Med Assoc; 2012 Jul; 110(7):449-52. PubMed ID: 23520668
[TBL] [Abstract][Full Text] [Related]
5. Severe complications after hypofractionated high dose rate intracavitary brachytherapy following external beam irradiation for oesophageal carcinoma.
Hama Y; Uematsu M; Shioda A; Suda A; Aida S; Kusano S
Br J Radiol; 2002 Mar; 75(891):238-42. PubMed ID: 11932217
[TBL] [Abstract][Full Text] [Related]
6. A phase I/II study of external beam radiation, brachytherapy and concurrent chemotherapy in localized cancer of the esophagus (RTOG 92-07): preliminary toxicity report.
Gaspar LE; Qian C; Kocha WI; Coia LR; Herskovic A; Graham M
Int J Radiat Oncol Biol Phys; 1997 Feb; 37(3):593-9. PubMed ID: 9112458
[TBL] [Abstract][Full Text] [Related]
7. Genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with Hypofractionated External beam radiotherapy for localized prostate cancer: an analysis to determine the correlation between dose-volume histogram parameters in HDR brachytherapy and severity of toxicity.
Ishiyama H; Kitano M; Satoh T; Kotani S; Uemae M; Matsumoto K; Okusa H; Tabata K; Baba S; Hayakawa K
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):23-8. PubMed ID: 19243900
[TBL] [Abstract][Full Text] [Related]
8. Radical radiotherapy incorporating a brachytherapy boost for the treatment of carcinoma of the thoracic oesophagus: results from a cohort of patients and review of the literature.
Churn M; Jones B; Myint AS
Clin Oncol (R Coll Radiol); 2002 Apr; 14(2):117-22. PubMed ID: 12069118
[TBL] [Abstract][Full Text] [Related]
9. Clinical comparison of two linear-quadratic model-based isoeffect fractionation schemes of high-dose-rate intracavitary brachytherapy for cervical cancer.
Wang CJ; Huang EY; Sun LM; Chen HC; Fang FM; Hsu HC; Changchien CC; Leung SW
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):179-89. PubMed ID: 15093915
[TBL] [Abstract][Full Text] [Related]
10. Long-term Toxicity and Health-related Quality of Life after Single-fraction High Dose Rate Brachytherapy Boost and Hypofractionated External Beam Radiotherapy for Intermediate-risk Prostate Cancer.
Shahid N; Loblaw A; Chung HT; Cheung P; Szumacher E; Danjoux C; Sankreacha R; Zhang L; Deabreu A; Mamedov A; Morton G
Clin Oncol (R Coll Radiol); 2017 Jul; 29(7):412-420. PubMed ID: 28190638
[TBL] [Abstract][Full Text] [Related]
11. Triple-tandem high-dose-rate brachytherapy for early-stage medically inoperable endometrial cancer: Initial report on acute toxicity and dosimetric comparison to stereotactic body radiation therapy.
Kauffmann G; Wu T; Al-Hallaq H; Hasan Y
Brachytherapy; 2017; 16(1):141-146. PubMed ID: 27866953
[TBL] [Abstract][Full Text] [Related]
12. Curative radiotherapy with high-dose-rate brachytherapy boost for localized esophageal carcinoma: dose-effect relationship of brachytherapy with the balloon type applicator system.
Yorozu A; Dokiya T; Oki Y; Suzuki T
Radiother Oncol; 1999 May; 51(2):133-9. PubMed ID: 10435804
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of the American Brachytherapy Society guidelines for the use of high-dose rate brachytherapy in the treatment of cervical carcinoma: is 45-50.4 Gy radiochemotherapy plus 31.8 Gy in six fractions high-dose rate brachytherapy tolerable?
Shakespeare TP; Lim KH; Lee KM; Back MF; Mukherjee R; Lu JD;
Int J Gynecol Cancer; 2006; 16(1):277-82. PubMed ID: 16445645
[TBL] [Abstract][Full Text] [Related]
14. Prospective randomized trial of HDR brachytherapy as a sole modality in palliation of advanced esophageal carcinoma--an International Atomic Energy Agency study.
Sur RK; Levin CV; Donde B; Sharma V; Miszczyk L; Nag S
Int J Radiat Oncol Biol Phys; 2002 May; 53(1):127-33. PubMed ID: 12007950
[TBL] [Abstract][Full Text] [Related]
15. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
[TBL] [Abstract][Full Text] [Related]
16. Dose-volume impact in high-dose-rate Iridium-192 brachytherapy as a boost to external beam radiotherapy for localized prostate cancer--a phase II study.
Pinkawa M; Fischedick K; Treusacher P; Asadpour B; Gagel B; Piroth MD; Borchers H; Jakse G; Eble MJ
Radiother Oncol; 2006 Jan; 78(1):41-6. PubMed ID: 16271785
[TBL] [Abstract][Full Text] [Related]
17. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
18. Brachytherapy for Buccal Cancer: From Conventional Low Dose Rate (LDR) or Mold Technique to High Dose Rate Interstitial Brachytherapy (HDR-ISBT).
Kotsuma T; Yamazaki H; Masui K; Yoshida K; Shimizutani K; Akiyama H; Murakami S; Isohashi F; Yoshioka Y; Ogawa K; Tanaka E
Anticancer Res; 2017 Dec; 37(12):6887-6892. PubMed ID: 29187469
[TBL] [Abstract][Full Text] [Related]
19. Combined external beam and low dose rate intraluminal radiotherapy in oesophageal cancer.
Caspers RJ; Zwinderman AH; Griffioen G; Welvaart K; Sewsingh EN; Davelaar J; Leer JW
Radiother Oncol; 1993 Apr; 27(1):7-12. PubMed ID: 7687066
[TBL] [Abstract][Full Text] [Related]
20. Effect and toxicity of endoluminal high-dose-rate (HDR) brachytherapy in centrally located tumors of the upper respiratory tract.
Harms W; Schraube P; Becker H; Latz D; Herth F; Fritz P; Wannenmacher M
Strahlenther Onkol; 2000 Feb; 176(2):60-6. PubMed ID: 10697652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
